Clinical Trial Update: Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of zanubrutinib and pemetrexed for relapsed or refractory primary and secondary central nervous system ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Alimta (pemetrexed)
• BRUKINSA (ZANUBRUTINIB)

Snippet

Sponsor: Baptist Health South Florida | Conditions: Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Status: RECRUITING